CureVac (CVAC) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
CureVac’s partner GSK has reported positive Phase 2 results from their seasonal influenza mRNA vaccine program, demonstrating strong immune responses and an acceptable safety profile. The vaccine, utilizing CureVac’s second-generation mRNA technology, is slated for Phase 3 trials, marking a significant milestone for CureVac. These developments could potentially enhance CureVac’s market position and offer new solutions for influenza prevention.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
